 |
|
|
|
| |
 |
|
|
| |
BR Pharma Appoints Adele Davis as Head of Clinical Trials
April 2008Pharmaceutical Outsourcing Firm Taps Industry Veteran to Lead Drug Procurement Programs
BOREHAMWOOD, U.K.
BR Pharma, a leader in the procurement of pharmaceutical products for comparator trials and named patient programs, today announced the appointment of Adele Davis to the new position of Head of Clinical Trials. Davis will be responsible for managing operations of the company’s Clinical Trials Procurement Team, heading project management of comparator drug procurement programs and cultivating new business opportunities.
“Adele’s worldwide clinical trial drug procurement expertise will be invaluable to BR Pharma and our U.S. business development arm, Pharmarama, as we continue to grow our business internationally,” said Rosemary Bensley, managing director of BR Pharma. “She brings a track record of success in planning and implementing comparator procurement projects and building strong relationships with customers and suppliers worldwide. We are delighted to welcome Adele to the executive team.”
Prior to joining BR Pharma, Davis was Head of Clinical Trial Supplies at ADAllen Pharma, Ltd., where she spent over five years helping to set up and run the firm’s clinical supplies division. In that role she managed complex clinical trials procurement projects, sourced drug supply along with related documentation, conducted customer and supplier audits and established processes that ensured project accuracy.
“BR Pharma is building a truly global business, and I am thrilled to join the organization at this exciting time in its history,” Davis said. “Pharmaceutical companies recognize the benefits of conducting clinical trials in emerging markets such as China, India and Eastern Europe. But the complexity of sourcing and procuring comparators for these studies requires specialized knowledge in areas such as blinding, packaging and regulatory documentation. BR Pharma has that knowledge. I look forward to working with Rosemary and the other members of the executive team as we execute our international business development strategy and continue to increase our market share.”
|
|
|
